Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Pr...
Lantern Pharma Inc. (LTRN)
Company Research
Source: Business Wire
Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all primary endpoints.LP-184 demonstrated clinical benefit in multiple highly aggressive cancers with a 54% disease control rate at or above therapeutic dose levels.Multiple Phase 1b/2 clinical trials are now being planned across cancer indications and supported by 3 FDA Orphan Drug, 2 FDA Fast Track Designations and a Rare Pediatric Disease Designation.Detailed webinar with management and KOL from Fox Chase Cancer Center highlighting the drug-candidate and patient insights can be found at "Inside The Data". DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-18
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Lantern Pharma (NASDAQ:LTRN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire
LTRN
Earnings
- 8/13/25 - Beat
LTRN
Sec Filings
- 11/13/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 9/23/25 - Form 8-K
- LTRN's page on the SEC website